Aldeyra Therapeutics
- Company typePublic
- Founded2005
- HeadquartersBurlington, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Aldeyra Therapeutics firmographics
Firmographics- Name
- Aldeyra Therapeutics
- Legal name
- Aldeyra Therapeutics, Inc.
- Website
- https://aldeyra.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Aldeyra Therapeutics industry classification
Industry- Product category
- Clinical-Stage Biotechnology / Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- Rare Ophthalmology Disorder Therapies (HLAIAIAK), Dermatology & Topical Skin Treatments (HLAIADAE)
Keywords
Where Aldeyra Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aldeyra Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage biotechnology company. Not yet commercially selling any products. Revenue expected from future sales of reproxalap and other pipeline candidates upon regulatory approval.
- Licensing/Partnership Revenue: AbbVie holds an exclusive option to collaborate on commercialization of reproxalap. If AbbVie exercises the option, Aldeyra could receive $100 million minus previous payments, with U.S. profits split 60%/40% in AbbVie's favor.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Aldeyra Therapeutics product offering
Product offeringCore offering
Aldeyra Therapeutics is a clinical-stage biotechnology company that develops small-molecule drug candidates targeting Reactive Aldehyde Species (RASP) to treat immune-mediated diseases. Its pipeline includes the lead candidate reproxalap (topical ocular therapy for dry eye disease), ADX-2191 (intraocular methotrexate for primary vitreoretinal lymphoma and retinitis pigmentosa), ADX-248 (oral therapy for atopic dermatitis and CNS/neuroinflammatory disease), and ADX-246 (intravitreal therapy for dry AMD and geographical atrophy). None of these candidates have yet received regulatory approval or generated commercial product sales.
Product overview
Aldeyra Therapeutics is a clinical-stage biotechnology company with a pipeline of RASP (Reactive Aldehyde Species) modulator drug candidates targeting immune-mediated diseases. The company's portfolio includes: reproxalap (topical ocular) for dry eye disease with an AbbVie option agreement; ADX-248 (oral) for atopic dermatitis, obesity/hypertriglyceridemia, and CNS diseases; ADX-246 (intravitreal injection) for age-related macular degeneration and geographical atrophy; and ADX-2191 (intraocular injection) for primary vitreoretinal lymphoma and retinitis pigmentosa (FDA Orphan-Drug Designated). The RASP modulator platform represents a novel approach targeting harmful reactive aldehyde species to treat inflammatory and neurodegenerative conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Reproxalap
Quantifiable outcome
- Stock declined 70.7% following FDA Complete Response Letter on March 17, 2026
- +1 more outcomes
Companies that use Aldeyra Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Aldeyra Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Aldeyra Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AbbViecoreAbbVie holds an exclusive option to collaborate on commercialization of reproxalap for dry eye disease. If AbbVie exercises the option, it could pay Aldeyra $100 million minus previous payments made, with U.S. profits split 60%/40% in AbbVie's favor. This represents a significant potential commercialization partnership for Aldeyra's lead pipeline candidate.
Scale indicators6 records
Recent moves6 records
Expansion highlights4 records
Aldeyra Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Bausch + Lomb: Major ophthalmology company with commercial dry eye disease products including Miebo (perfluorohexyloctane). Comparable as a direct competitor in the dry eye disease market with established sales infrastructure, providing the benchmark against which Aldeyra would compete if reproxalap is approved.
- AbbVie (Allergan Aesthetics): Global pharmaceutical company holding the option to commercialize reproxalap and owner of Restasis, the leading dry eye disease prescription. Comparable as both a potential commercial partner and the dominant incumbent in the dry eye disease market Aldeyra targets.
- Novartis: Global pharmaceutical company marketing Xiidra (lifitegrast) for dry eye disease. Comparable as a major incumbent in the dry eye disease market; also connected through Richard Douglas, Aldeyra's Chairman, who serves on Novartis's Novavax board connections.
- Sun Pharmaceutical Industries: Global pharmaceutical company marketing CEQUA (cyclosporine ophthalmic) for dry eye disease. Comparable as an established competitor in the dry eye disease prescription market with broader ophthalmology portfolio.
Direct peers
- Oyster Point Pharma: Clinical-stage ophthalmology company developing Tyrvaya (varenicline) nasal spray for dry eye disease. Directly comparable as a small-cap biotech focused on novel dry eye disease therapeutics, with a similar regulatory pathway and commercial challenges in a competitive market.
- Kala Bio: Clinical-stage ophthalmology company developing novel dry eye disease therapies using a mucus-penetrating particle technology. Comparable as a small-cap ophthalmology biotech focused on dry eye disease, with similar pre-commercial stage and reliance on partner commercialization.
Emerging players
- Aclaris Therapeutics: Clinical-stage biotech developing novel immunology therapies for dermatological and inflammatory conditions. Comparable as a similarly-sized immune-mediated disease biotech; also connected via board member Neal Walker, Aclaris's CEO.
- Tarsus Pharmaceuticals: Clinical-stage ophthalmology company developing novel therapies for eye conditions including Demodex blepharitis (Xdemvy). Comparable as a similarly-sized pre-commercial ophthalmology biotech navigating FDA approval and commercialization in eye care.
- Stealth BioTherapeutics: Clinical-stage biotech developing mitochondrial-targeted therapies for rare diseases. Comparable as a small-cap clinical-stage biotech; also connected via Ben Bronstein, an Aldeyra director, who previously served as CMO of Stealth BioTherapeutics.
- OrphoMed: Clinical-stage biotech developing therapies for rare inflammatory and immunologic diseases. Comparable as a small-cap clinical-stage biotech focused on immunology; also connected via board member Gary Phillips, OrphoMed's CEO.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Aldeyra Therapeutics social profiles
Digital presenceAldeyra Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aldeyra Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
Aldeyra Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aldeyra Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aldeyra Therapeutics
What does Aldeyra Therapeutics do?
Aldeyra Therapeutics is a clinical-stage biotechnology company that develops small-molecule drug candidates targeting Reactive Aldehyde Species (RASP) to treat immune-mediated diseases. Its pipeline includes the lead candidate reproxalap (topical ocular therapy for dry eye disease), ADX-2191 (intraocular methotrexate for primary vitreoretinal lymphoma and retinitis pigmentosa), ADX-248 (oral therapy for atopic dermatitis and CNS/neuroinflammatory disease), and ADX-246 (intravitreal therapy for dry AMD and geographical atrophy). None of these candidates have yet received regulatory approval or generated commercial product sales.
Is Aldeyra Therapeutics a public or private company?
Aldeyra Therapeutics is a public company. It is classified as public and is currently operating.
When was Aldeyra Therapeutics founded?
Aldeyra Therapeutics was founded in 2005. It employs 1 to 10 people.
Where is Aldeyra Therapeutics based?
Aldeyra Therapeutics is headquartered in Burlington, United States, in the North America region.
How does Aldeyra Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing/Partnership Revenue.
Who are Aldeyra Therapeutics's main competitors?
Broad incumbents on record are Bausch + Lomb, AbbVie (Allergan Aesthetics), Novartis and Sun Pharmaceutical Industries. Direct peers are Oyster Point Pharma and Kala Bio. Emerging players are Aclaris Therapeutics, Tarsus Pharmaceuticals, Stealth BioTherapeutics and OrphoMed.
Does Aldeyra Therapeutics have an API?
No public API is recorded for Aldeyra Therapeutics.
What industry is Aldeyra Therapeutics in?
Aldeyra Therapeutics's product category is Clinical-Stage Biotechnology / Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.